Discover how to reduce manufacturing variability, strengthen process control and overcome quality challenges to support scalable cell and gene therapy (CGT) development.
Accelerated development timelines, complex manufacturing processes and evolving regulatory expectations are increasing pressure on CGT developers to deliver consistent product quality while scaling production.
Join experts from Genezen and eXmoor Pharma as they explore practical approaches to defining critical quality attributes (CQAs), developing robust potency assays and strengthening analytical and control strategies.
The discussion will also examine how Quality by Design (QbD), automation and closed-system processing can improve reproducibility, alongside the potential of AI-powered digital twins, modular manufacturing and allogeneic platforms to address emerging manufacturing challenges.
Attend this webinar to explore how to:
- Improve manufacturing consistency by identifying and controlling sources of process variability.
- Strengthen analytical and quality strategies through effective CQA assessment, potency assays and QbD principles.
- Navigate scale-up and comparability challenges while maintaining process control under accelerated timelines.
- Evaluate emerging manufacturing technologies, including automation, closed systems and AI-powered digital twins, to support reproducibility and scalability.
Who should attend?
This webinar is suitable for senior professionals involved in CGT development and manufacturing, including:
- Manufacturing and Technical Operations leaders
- CMC and Process Development teams
- MSAT and Manufacturing Science professionals
- Quality and Regulatory leaders
- Process Engineering and Automation specialists
- Technology Transfer and Scale-up/Scale-out teams
Join industry experts to explore how manufacturers can accelerate CGT development while building the foundations for successful commercialisation.
The content presented in these sessions is intended for research use only and is not intended for use in diagnostic procedures. The views and opinions expressed in the recordings are those of the individual presenters and do not necessarily reflect the official policy, position, or claims of Bio-Rad Laboratories. Any clinical applications, test validations, or performance claims discussed are the sole responsibility of the presenting institution or speaker and do not reflect the views or endorsements of Bio-Rad Laboratories.
Any reference to clinical use, patient testing, or performance claims reflects the practices and experience of the individual institutions or researchers and should not be interpreted as endorsement by Bio-Rad.
Speakers
Dr Susan D’Costa serves as Chief Technical and Commercial Officer of Genezen. She is a molecular virologist with over 25 years of experience, including more than a decade in viral vector gene therapy. Her expertise spans viral vector analytics, process development, manufacturing, and team building. Before joining Genezen, Susan was CTO at Alcyone Therapeutics, leading viral vector CMC, device development, and technology partnerships.
Rob Scott is Head of Consultancy at eXmoor Pharma and an EU Qualified Person (QP). He has more than 25 years of experience across biopharmaceuticals, cell and gene therapies, and GMP quality systems. His expertise spans process development, facility and equipment qualification, QC and QA system development, aseptic validation, audit support and manufacturing compliance.
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand.
When will the panel discussion take place?
The webinar will be taking place on 19 November at 3pm (GMT).
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.
